Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease.
Attenuated plasma GH secretion during sleep and blunted GH responses to provocative stimuli have been observed in patients with Cushing's disease. Synthetic porcine galanin elicits GH secretion when given alone, and enhances the GH response to GHRH in normal human subjects. The aim of our study was to investigate the effects of galanin on the GH response to GHRH in patients with Cushing's disease. We studied 5 female subjects with untreated active Cushing's disease caused by micro-pituitary adenomas (age 43 +/- 6.7 years; BMI 30 +/- 0.7 kg/m2). Four normal adult females, matched for age and body weight with the patients with Cushing's disease, were studied as controls. Subjects underwent in random order: (1) infusion of synthetic porcine galanin IV, 500 micrograms in 100 mL; (2) infusion of saline, IV, 100 mL. A bolus of human GHRH(1-29)NH2 (Geref, Serono, Italy), 100 micrograms in 1 mL saline, was injected IV at 0 minutes. Patients with Cushing's disease showed blunted GH peaks after GHRH (1.2 +/- 0.4 micrograms/L) during saline infusion, as compared to normal controls (24.6 +/- 4.6 micrograms/L; p < 0.05). During galanin infusion a significantly enhanced GH response to GHRH, as compared with saline infusion, was observed in control subjects (GH peak: 51.4 +/- 9.8 micrograms/L; p < 0.05), but not in patients with Cushing's disease (GH peak: 2.3 +/- 0.6 micrograms/L). GH levels were significantly lower both after saline and after galanin in patients with Cushing's disease as compared to normal controls. Our data demonstrate that galanin is not able to enhance the GH response to GHRH in patients with Cushing's disease. That galanin cannot reverse this effect suggests that the mechanism of action of galanin is not via a decrease in somatostatin release by the hypothalamus.
Giustina
A
A
Cattedra di Clinica Medica, University of Brescia.
Bossoni
S
S
Bussi
A R
AR
Pozzi
A
A
Wehrenberg
W B
WB
D000236:Adenoma / Q000150:complications; D000328:Adult; D000704:Analysis of Variance; D003480:Cushing Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D005260:Female; D019004:Galanin; D013006:Growth Hormone / Q000096:biosynthesis*; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D009479:Neuropeptides / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000150:complications; D016037:Single-Blind Method; D013997:Time Factors
D009479:Neuropeptides; D010455:Peptides; D019004:Galanin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone